当前位置：
X-MOL 学术
›
Nutr. Diabetes
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial.
Nutrition & Diabetes ( IF 4.6 ) Pub Date : 2019-11-04 , DOI: 10.1038/s41387-019-0099-4 Sarang Jeong 1 , Jung Min Cho 1 , Young-In Kwon 2 , Seong-Chul Kim 3 , Dong Yeob Shin 4 , Jong Ho Lee 1
Nutrition & Diabetes ( IF 4.6 ) Pub Date : 2019-11-04 , DOI: 10.1038/s41387-019-0099-4 Sarang Jeong 1 , Jung Min Cho 1 , Young-In Kwon 2 , Seong-Chul Kim 3 , Dong Yeob Shin 4 , Jong Ho Lee 1
Affiliation
|
BACKGROUND
The antidiabetic and hypoglycemic effects of chitosan have been reported in previous studies. We have previously shown that chitosan oligosaccharide reduces postprandial blood glucose levels in vivo. We conducted a short-term crossover study to support the results of the previous study.
METHODS
The study was a randomized, double-blind, controlled crossover trial completed at one clinical research site. Subjects with impaired glucose tolerance and impaired fasting glucose and healthy subjects were randomly assigned to consume one of two different experimental test capsules that differed in only the sample source (GO2KA1 vs placebo), and all subjects were instructed to consume the 75 g sucrose within 15 min. After a 7-day interval, the subjects consumed the other capsules that were not consumed on the first day. We assessed blood glucose levels using a 2-h oral sucrose tolerance test. The study was registered at clinicaltrials.gov (NCT03650023).
RESULTS
The test group showed significantly lower blood glucose levels at 60 min (p = 0.010) and postprandial blood glucose areas under the curve (p = 0.012). The change in blood glucose levels at 60 min was significantly lower in the test group than in the placebo group (p = 0.017).
CONCLUSIONS
Based on the results of this study, the consumption of chitosan oligosaccharide (GO2KA1) supplements with a meal can effectively reduce postprandial blood glucose levels, which is relevant to the prevention of diabetes.
中文翻译：
壳寡糖 (GO2KA1) 可改善糖耐量受损和空腹血糖受损受试者以及健康受试者的餐后血糖反应：一项交叉随机对照试验。
背景技术壳聚糖的抗糖尿病和降血糖作用已在先前的研究中报道过。我们之前已经证明，壳寡糖可降低体内餐后血糖水平。我们进行了一项短期交叉研究来支持之前研究的结果。方法 该研究是一项在一个临床研究中心完成的随机、双盲、对照交叉试验。糖耐量受损、空腹血糖受损的受试者和健康受试者被随机分配服用两种不同的实验测试胶囊中的一种，仅样本来源不同（GO2KA1 与安慰剂），并且所有受试者都被指示在 15 天内服用 75 g 蔗糖。分钟。间隔 7 天后，受试者服用第一天未服用的其他胶囊。我们使用 2 小时口服蔗糖耐受试验评估血糖水平。该研究已在 ClinicalTrials.gov 上注册 (NCT03650023)。结果 测试组在 60 分钟时的血糖水平 (p = 0.010) 和餐后血糖曲线下面积 (p = 0.012) 显着降低。60 分钟时测试组的血糖水平变化显着低于安慰剂组 (p = 0.017)。结论根据本研究结果，随餐补充壳寡糖（GO2KA1）可有效降低餐后血糖水平，与预防糖尿病有关。
更新日期：2019-11-04
中文翻译：
壳寡糖 (GO2KA1) 可改善糖耐量受损和空腹血糖受损受试者以及健康受试者的餐后血糖反应：一项交叉随机对照试验。
背景技术壳聚糖的抗糖尿病和降血糖作用已在先前的研究中报道过。我们之前已经证明，壳寡糖可降低体内餐后血糖水平。我们进行了一项短期交叉研究来支持之前研究的结果。方法 该研究是一项在一个临床研究中心完成的随机、双盲、对照交叉试验。糖耐量受损、空腹血糖受损的受试者和健康受试者被随机分配服用两种不同的实验测试胶囊中的一种，仅样本来源不同（GO2KA1 与安慰剂），并且所有受试者都被指示在 15 天内服用 75 g 蔗糖。分钟。间隔 7 天后，受试者服用第一天未服用的其他胶囊。我们使用 2 小时口服蔗糖耐受试验评估血糖水平。该研究已在 ClinicalTrials.gov 上注册 (NCT03650023)。结果 测试组在 60 分钟时的血糖水平 (p = 0.010) 和餐后血糖曲线下面积 (p = 0.012) 显着降低。60 分钟时测试组的血糖水平变化显着低于安慰剂组 (p = 0.017)。结论根据本研究结果，随餐补充壳寡糖（GO2KA1）可有效降低餐后血糖水平，与预防糖尿病有关。
京公网安备 11010802027423号